Combination Therapy with Oleanolic Acid and Metformin as a Synergistic Treatment for Diabetes

• DOI: 10.1155/2015/973287
• Publication Date: 2015-02-19T16:03:29Z
• Authors: Xue Wang; Yupeng Chen; Daoud Abdelkader; Waseem Hassan; Hongbin Sun; Jun Liu
• Keywords: Male; Diseases of the endocrine glands. Clinical endocrinology; Diabetes Mellitus, Experimental; Mice; 03 medical and health sciences; Animals; Homeostasis; Hypoglycemic Agents; Insulin; Oleanolic Acid; Phosphorylation; 0303 health sciences; Body Weight; Organ Size; RC648-665; Hypoglycemia; Metformin; 3. Good health; Mice, Inbred C57BL; Disease Models, Animal; Glucose; Diabetes Mellitus, Type 2; Liver; Drug Therapy, Combination; Biomarkers; Research Article

Type 2 diabetes is a chronic disease that cannot be treated adequately using the known monotherapies, especially when progresses to an advanced stage. In this study, we explore possibility of treating with novel combination approach oleanolic acid (OA), glycogen phosphorylase (GP) inhibitor, and metformin. Db/db mice were randomly divided into four groups: db/db control group, OA (250 mg/kg), metformin (100 All for weeks. The effects treatments on glucose homeostasis measured OGTT, assessment insulin sensitivity signaling in liver, hepatic production. Combination therapy significantly reduced blood levels improved liver pathology compared monotherapy diabetic mouse model. We also found increased mRNA expression synthesis decreased GP, PGC-1α, PEPCK1, G-6-Pase levels. addition, phosphorylation AKT, PI3K, AMPK, ACC protein G-6-Pase, TORC those either monotherapy. mTOR CREB. Our results suggest has synergistic symptoms by improving homeostasis.